https://www.prognyx.com/blog/pluvicto-approved-with-an-arpi-in-psma-positive-mhspc-radioligand-therapy-arrivePrognyxen2026-08-04Pluvicto approved with an ARPI in PSMA-positive mHSPC: radioligand therapy arrives in first-line metastatic prostate cancer